DOI: 10.1111/jdv.19925 ISSN: 0926-9959

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

Bruce Strober, Andrew Blauvelt, Richard B. Warren, Kim A. Papp, April W. Armstrong, Kenneth B. Gordon, Akimichi Morita, Andrew F. Alexis, Mark Lebwohl, Peter Foley, Renata M. Kisa, Elizabeth Colston, Tao Wang, Subhashis Banerjee, Diamant Thaçi
  • Infectious Diseases
  • Dermatology
Show PDF Cite

Abstract

Background

Two phase 3 trials, POETYK PSO‐1 and PSO‐2, previously established the efficacy and overall safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in plaque psoriasis.

Objectives

To further assess the safety of deucravacitinib over 52 weeks in the pooled population from these two trials.

Methods

Pooled safety data were evaluated from PSO‐1 and PSO‐2 in which patients with moderate‐to‐severe plaque psoriasis were randomized 1:2:1 to receive oral placebo, deucravacitinib or apremilast.

Results

A total of 1683 patients were included in the pooled analysis. Adverse event (AE) incidence rates were similar in each treatment group, serious AEs were low and balanced across groups, and discontinuation rates were lower with deucravacitinib versus placebo or apremilast. No new safety signals emerged with longer deucravacitinib treatment. Exposure‐adjusted incidence rates of AEs of interest with placebo, deucravacitinib and apremilast, respectively, were as follows: serious infections (0.8/100 person‐years [PY], 1.7/100 PY, and 1.8/100 PY), major adverse cardiovascular events (1.2/100 PY, 0.3/100 PY, and 0.9/100 PY), venous thromboembolic events (0, 0.2/100 PY, and 0), malignancies (0, 1.0/100 PY and 0.9/100 PY), herpes zoster (0.4/100 PY, 0.8/100 PY, and 0), acne (0.4/100 PY, 2.9/100 PY, and 0) and folliculitis (0, 2.8/100 PY, and 0.9/100 PY). No clinically meaningful changes from baseline in mean levels, or shifts from baseline to CTCAE grade ≥3 abnormalities, were reported in laboratory parameters with deucravacitinib.

Conclusions

Deucravacitinib was well‐tolerated with acceptable safety over 52 weeks in patients with psoriasis.

More from our Archive